Hot Pursuit     08-Aug-22
Advanced Enzyme drops after Q1 PAT slides 56% YoY
Advanced Enzyme Technologies fell 4.62% to Rs 279.60 after the company's consolidated profit after tax de-grew by 56% to Rs 17.6 crore during Q1 FY23 compared with Rs 39.7 crore during the Q1 FY22.
Revenue from operations on consolidated basis decreased to Rs 121.1 crore in the Q1 FY23 from Rs 137 crore in the Q1 FY22, declining by 12% on y-o-y basis and 8% on q-o-q basis.

Consolidated EBITDA during Q1 FY23 stands at Rs 30.9 crore as against Rs 62.7 crore during Q1 FY22, decrease of 51%. Profit before tax (PBT) stands at Rs 23.7 crore during Q1 FY23 as against Rs 54.7 crore in Q1 FY22, decline of 57%.

EBITDA margin stands at 26%, PBT margin stands at 20% and PAT margin stands at 15% during the quarter.

The revenue from human nutrition segment declined by 10% to Rs 80.7 crore in Q1 FY23 as compared to Rs 89.2 crore in Q1 FY22. This decline is accounted on behave of Probiotics and Bio-catalysis division.

The Animal nutrition segment delivered a growth of 11% to Rs 15.6 crore in Q1 FY23 as against Rs 14.1 crore in Q1 FY22.

The Bio-Processing segment underperformed by ~10% during the quarter, it accounted for Rs 18.3 crore in Q1 FY23 as compared to Rs 20.3 crore in Q1 FY22.

The specialized manufacturing segment contributed 5% in the pie which is Rs 6.5 crore to the revenue during the quarter, a decline of 52% on y-o-y basis.

The total revenue comprises of International sales amounting to Rs 66.2 crore in Q1 FY23 as compared to Rs 79.3 crore in Q1 FY22, a decline of 17%. The revenue declined by 14% in Americas, 37% in Europe, 90% in rest of the world while it registered a strong growth of 57% in Asia (ex-India).

Domestic sales accounted for Rs 55 crore in Q1 FY23 as compared to Rs 57.7 crore in Q1 FY22, it de-grew by 5%. The domestic sales constituted about 45% of revenue from operations during Q1 FY23 as compared to 42% during Q1 FY22. International sales were 55% of revenue from operations during Q1 FY23 as compared to 58% during Q1 FY22.

In its outlook, Advanced Enzymes said it will continue to focus on all three divisions - human nutrition, animal nutrition and bio-processing including developing, adding and launching more products in the target market of probiotics. The company is confident that its existing capacities and capital investments would serve well to expand its enzymes and probiotics business.

Advanced Enzyme Technologies is a research driven company with global leadership in the manufacturing of enzymes and probiotics. The company aims to replace traditionally used chemicals with eco-friendly enzymatic solutions.

Previous News
  Advanced Enzyme Technologies fixes record date for final dividend
 ( Market Beat - Reports 25-Jun-24   18:39 )
  Advanced Enzyme Tech gains after strong Q4 performance
 ( Hot Pursuit - 15-May-23   10:08 )
  Advanced Enzyme Technologies fixes record date for final dividend
 ( Market Beat - Reports 10-Aug-21   17:26 )
  Advanced Enzyme enters into distribution partnership with Azelis Singapore
 ( Corporate News - 15-Dec-21   10:46 )
  Advanced Enzyme Technologies consolidated net profit declines 2.73% in the March 2020 quarter
 ( Results - Announcements 30-May-20   14:57 )
  Advanced Enzyme Techs. schedules AGM
 ( Corporate News - 08-Jul-23   17:36 )
  Advanced Enzyme Techs. to table results
 ( Corporate News - 30-Jul-22   11:56 )
  Apcotex Industries Ltd leads gainers in 'A' group
 ( Hot Pursuit - 13-Sep-21   12:00 )
  Advanced Enzyme Technologies consolidated net profit rises 20.16% in the September 2020 quarter
 ( Results - Announcements 12-Nov-20   13:53 )
  Advanced Enzymes rises after Q1 PAT jumps 67% YoY to Rs 29 crore
 ( Hot Pursuit - 14-Aug-23   12:05 )
  Advanced Enzyme soars on positive breakthrough in RCTs of COVID-fatigue treating enzymes
 ( Hot Pursuit - 13-Sep-21   11:15 )
Other Stories
  Dhanlaxmi Bank gains as gross advances rises 6% YoY in Q1 FY25
  05-Jul-24   15:27
  HDFC Bank Ltd leads losers in 'A' group
  05-Jul-24   15:00
  Shilpa Medicare sizzles after Unicycive gets positive results in clinical trials of OLC
  05-Jul-24   14:52
  Manugraph India Ltd leads losers in 'B' group
  05-Jul-24   14:45
  NSE SME Nephro Care India rallies on listing day
  05-Jul-24   14:45
  ESAF SFB total deposits jumps 33% YoY in Q1
  05-Jul-24   14:43
  Utkarsh SFB deposits climb 30% YoY in Q1 FY25
  05-Jul-24   14:35
  Volumes soar at Medplus Health Services Ltd counter
  05-Jul-24   14:30
  Financials stocks slide
  05-Jul-24   14:00
  Banking stocks edge lower
  05-Jul-24   14:00
Back Top